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Abstract
The majority of MDMA (ecstasy) recreational users also consume cannabis. Despite the rewarding effects that both drugs
have, they induce several opposite pharmacological responses. MDMA causes hyperthermia, oxidative stress and neuronal
damage, especially at warm ambient temperature. However, THC, the main psychoactive compound of cannabis, produces
hypothermic, anti-inflammatory and antioxidant effects. Therefore, THC may have a neuroprotective effect against MDMA-
induced neurotoxicity. Mice receiving a neurotoxic regimen of MDMA (20 mg/kg 64) were pretreated with THC (3 mg/kg
64) at room (21uC) and at warm (26uC) temperature, and body temperature, striatal glial activation and DA terminal loss
were assessed. To find out the mechanisms by which THC may prevent MDMA hyperthermia and neurotoxicity, the same
procedure was carried out in animals pretreated with the CB1 receptor antagonist AM251 and the CB2 receptor antagonist
AM630, as well as in CB1,C B 2 and CB1/CB2 deficient mice. THC prevented MDMA-induced-hyperthermia and glial activation
in animals housed at both room and warm temperature. Surprisingly, MDMA-induced DA terminal loss was only observed in
animals housed at warm but not at room temperature, and this neurotoxic effect was reversed by THC administration.
However, THC did not prevent MDMA-induced hyperthermia, glial activation, and DA terminal loss in animals treated with
the CB1 receptor antagonist AM251, neither in CB1 and CB1/CB2 knockout mice. On the other hand, THC prevented MDMA-
induced hyperthermia and DA terminal loss, but only partially suppressed glial activation in animals treated with the CB2
cannabinoid antagonist and in CB2 knockout animals. Our results indicate that THC protects against MDMA neurotoxicity,
and suggest that these neuroprotective actions are primarily mediated by the reduction of hyperthermia through the
activation of CB1 receptor, although CB2 receptors may also contribute to attenuate neuroinflammation in this process.
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Introduction
3,4-Methylenedioxymethamphetamine (MDMA), commonly
known as ecstasy, is a widely used recreational drug with low
addictive potential, but with severe neurotoxic effects after
prolonged use [1]. MDMA produces the loss of 5-HT nerve
terminals when administered to primates or rats [2,3], and the
degeneration of dopamine (DA) nerve terminals when adminis-
tered to mice [4]. MDMA also induces hyperthermia [5], which
enhances neurotoxicity. In addition, MDMA-induced hyperther-
mia increases at warm ambient temperature, what, consequently,
aggravates axonal degeneration. High temperature enhances the
formation and uptake of MDMA toxic metabolites that increase
oxidative stress [6], causing nerve terminal damage [7,8], and
leading to neuroinflammation manifested by glial activation
[9,10], and eventually axonal degeneration. The strong influence
of ambient temperature on MDMA neurotoxicity is of clinical
interest since MDMA is frequently consumed in dance clubs with
warm ambient temperatures [11], where the neurotoxic effects of
the drugs may be exacerbated. One of the most effective
mechanisms to minimize MDMA neurotoxicity is to reduce
hyperthermia by decreasing ambient temperature [12] or using
antithermic drugs to control body temperature [9]. However,
these drugs are rarely consumed by MDMA users. Interestingly,
one of the drugs most frequently consumed together with MDMA
is cannabis [13,14]. D
9-tetrahydrocannabinol (THC), the main
psychoactive compound of cannabis, has widely reported hypo-
thermic [15], anti-inflammatory [16] and antioxidant [17]
properties. Indeed, MDMA and THC show many opposite
pharmacological effects. MDMA causes hyperlocomotion, hyper-
thermia, anxiety, and neurotoxicity [5], whereas THC induces
hypolocomotion, hypothermia, anxiolytic, and neuroprotective
properties [15]. Several studies in animal models demonstrate that
the combination of MDMA and THC counterbalances many of
their pharmacological effects. THC attenuated MDMA-induced
hyperlocomotion, hyperthermia, and anxiety in rats [18], and
MDMA reduced THC withdrawal syndrome in mice [19].
However, the neuroprotective effects of THC on MDMA
neurotoxicity have not yet been explored. The opposite effects of
cannabis and MDMA suggest that THC may provide some degree
of protection against the neurotoxic effects of MDMA [20,21].
Therefore, in the present study, we investigate if hypothermic and
neuroprotective properties of THC may prevent the neurotoxic
effects of MDMA in mice.
Materials and Methods
Animals
We used 9 to 12 week old male C57BL/6 mice for this study.
Mice were either wild-type (Charles River, France) or deficient in
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were housed in a temperature (21u or 26u61uC), humidity
(55%610%), and light-cycle controlled room.
Food and water were available ad libitum. Light was on between
8:00 am and 8:00 pm, and the experiments took place during the
light phase. All animal care and experimental procedures were
conducted according to the guidelines of the European Commu-
nities Directive 86/609/EEC regulating animal research and were
approved by the local ethical committee (CEEA-PRBB).
Drugs
MDMA hydrochloride (Lipomed, A.G., Arlesheim, Switzer-
land) was dissolved in 0.9% saline and administered at 20 mg/kg,
i.p. four times every 2 h. THC (THC Pharm, Frankfurt,
Germany) was dissolved in a solution of 5% ethanol, 5%
cremophor EL (Sigma Chemical, Madrid, Spain) and 90%
physiological saline (0.9%), and administered at 3 mg/kg, i.p.
1 h before each MDMA injection. The CB1 receptor antagonist
AM251 and the CB2 receptor antagonist AM630 (Tocris
Bioscience, Bristol, UK) were dissolved in a solution of 5%
DMSO, 5% Tween 80 (Sigma-Aldrich, Madrid Spain) and 90%
physiological saline, and administered at 1 mg/kg, i.p. 15 min
before each THC injection. All these drugs were administered in a
volume of 0.1 ml/10 g. Ketamine hydrochloride (100 mg/kg;
Imalge `ne 1000H, Rho ˆne Me ´rieux, Lyon, France) and xylazine
hydrochloride (20 mg/kg; Sigma Chemical Co., Madrid, Spain)
were mixed and dissolved in ethanol and water (1:9). This
anesthetic mixture was injected in a volume of 0.2 ml/10 g body
weight i.p., and used for intracardiac perfusion.
Experimental Procedure
Animals were injected with MDMA (20 mg/kg, i.p.) or saline
every 2 h for a total of 4 injections. One hour before each MDMA
administration, animals received an injection of THC (3 mg/kg,
i.p.) or its corresponding vehicle. A group of animals were also
pretreated with the CB1 receptor antagonist AM 251 or the CB2
receptor antagonist AM 630 15 min before each THC injection.
Body temperature was determined 30 min after the first MDMA
injection. 48 h after the last MDMA injection, animals were
sacrificed for immunostaining or western blot analysis.
Body Temperature
Rectal temperature was measured in animals housed at 21 and
at 2661uC and treated with THC and MDMA or their
corresponding vehicles. Body temperature was measured by
placing an electronic thermocouple flexible rectal probe (Panlab,
Madrid, Spain) in the rectum for 10 s. Temperature was measured
30 min after the first MDMA injection. In order to determine the
mechanism by which THC prevents MDMA-induced hyperther-
mia, two additional experiments were performed; (1) temperature
was recorded in animals housed at 2661uC and treated with the
CB1 receptor antagonist AM251 or the CB2 receptor antagonist
AM630, at 1 mg/kg 15 min before THC injection, and (2) body
temperature was measured in CB1,C B 2 and double CB1/CB2
knockout mice housed 2661uC and treated with THC and
MDMA.
Immunostaining
Activated microglia and astrocytes, and DA axons were
identified by immunohistochemistry in the striatum of animals
housed at 21 and 2661uC and treated with MDMA and THC.
Mice were anesthetized 48 h after the last MDMA injection with a
ketamine/xylazine mixture and transcardially perfused with 0.1 M
phosphate buffer containing 4% paraformaldehyde. Brains were
removed and postfixed in the same solution for four hours and
cryoprotected in 30% sucrose overnight. After freezing in dry ice,
brains were sliced into 30-mm thick coronal sections containing the
striatum. Sections were preincubated for 30 min in 20% H2O2
(Sigma-Aldrich, Spain), and then incubated for 2 h in a solution of
3% normal goat serum (Vector Laboratories, Inc., Burlingame,
CA) and 0.3% triton X-100 (Sigma-Aldrich, Spain). Activated
microglia was detected with rat anti-mouse CD11b (1:100;
Serotec, Oxford, UK), astrocytes were detected with polyclonal
rabbit anti-glial fibrillary acidic protein (1:1000; GFAP) (Dako,
Glostrup, Denmark), and DA axons were detected with mouse
anti-TH (1: 5000; Sigma-Aldrich, Spain). To visualize anti-CD11b
and anti-TH primary antibodies, biotinylated secondary antibod-
ies to rat or mouse Igs were applied for 1 h, followed by incubation
with avidin/biotin reagent (Vector Laboratories, Inc., Burlingame,
CA) for 2 h. Sections were stained with diaminobenzidine-HCl
(DAB) and H2O2. A fluorescent Alexa FluorH 488 secondary
antibody (Invitrogen, Eugene, OR) was used to visualize anti-
GFAP primary antibody. Analysis of CD11b and GFAP
immunostaining in the striatal region was carried out with Image
J software [24]. Briefly, the area comprising the striatum was
selected and the background was subtracted by adjusting detection
threshold density considering just the signal density above the
threshold. The number of pixels per area was measured
automatically, and the percentage of stained area was determined.
Measurements were performed in 3 different slices from the same
animal, the average was calculated, and the data were expressed as
percentage of the stained area.
Western Blot Analysis
Analysis of protein levels of tyrosine hydroxylase (TH),
tryptophan hydroxylase (TrH), serotonin transporter (SERT),
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the
striatum, as well as the levels of TrH and SERT in prefrontal
cortex and hippocampus of animals housed at 21 or 2661uC and
treated with THC and MDMA were analyzed by western blot.
Animals were sacrificed 48 h after the last MDMA injection, and
the striatum was dissected. Samples from all animals were
processed in parallel to minimize inter-assay variations. Frozen
brain areas were dounce-homogenized in 30 volumes of lysis
buffer (50 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 10%
glycerol, 1 mmol/L EDTA, 1 mg/mL aprotinin, 1 mg/mL
leupeptine, 1 mg/mL pepstatin) plus 1% Triton X-100. After
10 min incubation at 4uC, samples were centrifuged at 16000 g
for 30 min to remove insoluble debris. Supernatant protein
contents were determined by DC-micro plate assay (Bio-Rad,
Madrid, Spain), following the manufacturer’s instructions.
Equal amounts of brain lysates were mixed with denaturing 5x
Laemmli loading buffer and boiled for 5 min at 95uC. Samples
with equal amounts of total protein (20 mg per lane) were
separated in 10% sodium dodecyl sulfate-polyacrylamide gel
before electrophoretic transfer onto immobilon membrane (Milli-
pore, Billerica MA). Membranes were blocked for 1 h at room
temperature in Tris-buffered saline (TBS) (100 mmol/L NaCl,
10 mmol/L Tris, pH 7.4) with 0.1% Tween-20 (TBS-T) and 5%
non-fat milk. Afterwards, membranes were incubated for 2 h with
mouse anti-TH (1:5000; Sigma-Aldrich, Spain), rabbit anti-SERT
(1:1000), sheep anti TrH (1:1000) (Millipore, Billerica MA), and
mouse anti-GAPDH (1:5000) (Santa Cruz Biotechnology, Santa
Cruz, CA) primary antibodies. Bound antibodies were detected
with horseradish peroxidase-conjugated and anti-mouse, anti-
rabbit (Pierce, Spain; diluted), and anti-sheep (1:2500; Santa Cruz
Biotechnology, Santa Cruz, CA) secondary antibodies and
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Signal, Pierce, Spain). Only immunoblots showing similar amount
of GAPDH in all lanes were considered. The relevant immuno-
reactive bands were quantified after acquisition on a Chemilumi-
nescent Imaging with Chemi-Doc XRS, controlled by Image
Gauge software (Fuji, Japan). Data was expressed as the per-
centage of the band intensity compared to the control.
Statistical Analysis
Differences in body temperature, and microglia and astrocytes
staining between the different genotypes were compared by two-
way ANOVA with treatment and genotype as between-subjects
factors of variation, followed by one-way ANOVA and subsequent
post hoc analysis (Tukey’s test). Differences in body temperature and
glial staining between animals housed at different ambient
temperatures were compared by two-way ANOVA with treatment
and ambient temperature as between-subjects factors of variation,
followed by one-way ANOVA (Table 1 and 2). Differences in body
temperature of animals housed at 21uC, and microglia and
astrocytes staining, TH, TrH and SERT protein levels of animals
housed at 26uC were compared by one-way ANOVA followed by
post hoc analysis (Tukey’s test). In all the experiments, differences
were considered significant if the probability of error was less than
5%.
Results
Effects of THC on MDMA Treatment at Room
Temperature (2161uC)
THC reverses the moderated hyperthermia induced by
MDMA at room temperature. A baseline body temperature
of 37.560.08uC was recorded in all animals housed at 2161uC.
One hour after baseline, animals were injected with THC or
vehicle followed by MDMA or saline. Body temperature was
measured 30 min after MDMA injection (Fig. 1). Animals treated
with MDMA showed a statistically significant increase in body
temperature compared to the vehicle-treated group (p,0.05). In
contrast, a reduction of body temperature was observed in animals
treated with THC (p,0.05). Likewise, THC significantly reduced
body temperature in MDMA-treated animals when compared to
MDMA-treated mice (p,0.001), and when compared with the
saline-treated group (p,0.001) (Table 1).
THC prevents microglia and astrocytes activation in
MDMA-treated mice, mainly by CB1 but also by CB2
receptor-mediated mechanism. The activation of both
microglia and astrocytes was evaluated in the striatum of mice
housed at room temperature (2161uC) and treated with THC and
MDMA. Staining for activated microglia with an antibody for
CD11b (Fig. 2a–c) and for astrocytes with an antibody for GFAP
(Fig. 3a–c) showed that MDMA induced a marked glial activation
and that THC completely prevented microglia and astrocytes
activation induced by MDMA administration. THC alone had no
effect on microglia or astrocytes staining (data not shown). To
determine the mechanism by which THC prevents microglia and
astrocytes activation, CB1 (Fig. 2 and 3d–f), CB2 (Fig. 2 and 3g–i)
and double CB1/CB2 (Fig. 2 and 3j–l) knockout mice were treated
with a THC and MDMA regimen. THC was unable to inhibit
microglia and astrocytes activation in CB1 and CB1–CB2 mutant
mice (Fig. 2 and 3d–f and j–l). However, THC partially suppressed
microglial activation in CB2 knockout mice treated with MDMA,
and a similar effect was observed with astrocytes activation (Fig. 2
and 3g–i). These results suggest that THC prevented MDMA-
induced glial activation by activating CB1 receptor, and that the
activation of CB2 receptor by THC partially contributes to the
suppression of MDMA-induced microglial and astrocytes
activation (Table 1 and 2).
MDMA does not cause visible damage in striatal DA
terminals at room temperature. To evaluate DA axonal
damage, TH levels were evaluated in the striatum of mice treated
with THC and MDMA, and housed at 2161uC (Fig. 4). The
structure of the striatum (Fig. 4a) and the content of TH (Fig. 4b)
were similar between MDMA and saline treated animals (Table 1).
These results suggest that MDMA treatment at room temperature
does not cause a significant loss of DA terminals. THC alone had
no effects on the structure of the striatum or the levels of TH (data
not shown).
Effects of THC on MDMA Treatment at Warm
Temperature (2661uC)
THC reverses MDMA induced hyperthermia at warm
temperature by a CB1 receptor mechanism. Body
temperature was measured in animals housed at 2661uC. These
animals showed a baseline core temperature of 37.860.05uC,
which was similar to basal body temperature of animals housed at
21uC (37.560.08uC). This result suggests that increased ambient
temperature does not affect basal body temperature. After baseline
recordings, wild-type animals were injected with THC followed by
MDMA 1 h later, and body temperature was measured 30 min
after the MDMA injection (Fig. 5a).
MDMA administration at 26uC produced a significant
hyperthermia when compared to the vehicle-treated group
(p,0.001), whereas THC alone produced significant hypothermia
when compared with control animals (p,0.01). However, body
temperature in MDMA-treated animals receiving THC was
significantly lower than in animals treated with MDMA alone
(p,0.01) and similar to animals treated with vehicle. Thus, THC
significantly reduced MDMA-induced hyperthermia at warm
temperature (Table 2).
Body temperature of animals housed at 21uC and 26uC were
compared (Fig. 5b). No significant differences in core temperature
were observed between animals housed at 21uC and at 26uC and
treated with vehicle or THC. However, MDMA-treated animals
showed a significant enhancement in body temperature when
housed at 26uC( p ,0.001), and this effect was also observed in
MDMA-treated animals receiving THC (p,0.01) (Table 1 and 2).
These results indicate that warm ambient temperature potentiates
the hyperthermic effects of MDMA, but does not affect
hypothermic effects of THC.
Body temperature was also measured in animals pretreated with
the CB1 receptor antagonist AM251 (Fig. 5c) and the CB2 receptor
antagonist AM630 (Fig. 5d) receiving THC and MDMA and
housed at 2661uC. AM251 blocked the effect of THC on body
temperature. Therefore, THC did not prevent MDMA-induced
hyperthermia in these mice. Conversely, THC induced hypother-
mia and prevented MDMA-induced hyperthermia in animals
pretreated with the CB2 antagonist AM630 (Table 1).
Body temperature was also recorded in CB1,C B 2 and double
CB1/CB2 knockout mice administered with THC and MDMA
(Fig. 5a). Two-way ANOVA (Table 2), and subsequent post hoc
(Tukey’s test) analysis revealed that vehicle-treated CB1,C B 2 and
double CB1/CB2 knockout mice showed similar body temper-
ature than wild-type mice. Moreover, MDMA induced similar
hyperthermia in CB1,C B 2 and CB1/CB2 knockout mice than in
wild-type mice. On the contrary, THC induced hypothermia in
wild-type and CB2 knockout mice, but not in CB1 and CB1–CB2
deficient mice. Consequently, while THC prevented MDMA-
induced hyperthermia in wild-type and CB2 knockout mice, it
was unable to prevent MDMA-induced hyperthermia in mice
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prevents MDMA-induced hyperthermia through the activation
of CB1 receptor.
THC prevents microglia and astrocytes activation in
MDMA-treated mice housed at warm temperature.
Microglia and astrocytes activation was evaluated in the striatum of
animals housed at 2661uC after treatment with THC and MDMA
(Figure 6). Microglia (Fig. 6a) and astrocytes (Fig. 6b) were significantly
activated in MDMA-treated animals housed at 26uC. However, THC
suppressed MDMA-induced microglia and astrocytes activation
in animals housed at warm temperature. After, MDMA-induced
microglia and astrocytes activation of animals housed at 26uCw a s
compared with animals housed at 21uC. Although the intensity of glial
activation was similar at 21 and at 26uC, the area stained with CD11b
and astrocytes activation was significantly wider in animals housed at
26uC( T a b l e2 ) .
THC protects against DA terminal loss induced by
MDMA at warm ambient temperature by CB1 receptor
activation. The integrity of DA terminals was evaluated in
animals housed at 2661uCa n dt r e a t e dw i t hT H Ca n dM D M A
Table 1. One-way ANOVA calculated for body temperature, CD11b and GFAP staining and TH levels at 21 and 26uC.
Factor F-value p-value
Body temperature (21uC) Treatment F(1, 39)=20.595 ,0.001
CD11b (21uC) Genotype vehicle F(3, 21)=0.959 n.s.
MDMA F(3, 27)=0.449 n.s.
THC+MDMA F(3, 15)=49.549 ,0.001
Treatment WT F(2,26)=38.656 ,0.001
CB1 KO F(2, 12)=25.853 ,0.001
CB2 KO F(2, 12)=32.976 ,0.001
CB1-CB2 KO F(2, 13)=55.084 ,0.001
GFAP (21uC) Genotype vehicle F(3, 19)=0.959 n.s.
MDMA F(3, 26)=1.028 n.s.
THC+MDMA F(3, 14)=17.375 ,0.001
Treatment WT F(2, 21)=51.671 ,0.001
CB1 KO F(2, 13)=23.213 ,0.001
CB2 KO F(2, 13)=25.361 ,0.001
CB1-CB2 KO F(11, 187)=121.025 ,0.01
TH (21uC) Treatment F(2, 9)=4.434 n.s.
Body temperature (26uC) Genotype vehicle F(3, 28)=0.678 n.s.
THC F(3, 28)=5.006 ,0.01
MDMA F(3, 35)=1.026 n.s.
THC+MDMA F(3, 32)=7.010 ,0.001
Treatment WT F(3, 32)=23.044 ,0.001
CB1 KO F(3, 29)=11.080 ,0.001
CB2 KO F(3, 37)=16.899 ,0.001
CB1-CB2 KO F(3, 22)=42.854 ,0.001
AM251 Treatment F(5, 39)=18.028 ,0.001
AM630 Treatment F(5, 43)=14.583 ,0.001
Body temperature (21 vs 26uC) Ambient temperature vehicle F(1, 22)=1.519 n.s.
THC F(1, 20)=0.019 n.s.
MDMA F(1, 22)=16.831 ,0.001
THC+MDMA F(1, 24)=12.906 ,0.01
CD11b (26uC) Treatment F(2, 9)=61.087 ,0.001
GFAP (26uC) Treatment F(2, 9)=60.350 ,0.001
TH levels (26uC) Treatment WT F(2, 9)=72.558 ,0.001
CB1 KO F(2, 9)=80.098 ,0.001
CB2 KO F(2, 9)=151.349 ,0.001
CB1-CB2 KO F(2, 9)=30.274 ,0.001
AM251 Treatment F(3, 12)=30.274 ,0.001
AM630 Treatment F(3, 12)=43.394 ,0.001
One-way ANOVA for genotype, treatment or ambient temperature as between-subject factors. See Materials and methods for details. WT: wild-type; KO: knockout; n.s.:
non-significant.
doi:10.1371/journal.pone.0009143.t001
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striatum was notably altered in mice treated with MDMA
(Fig 7a), while the striatum integrity of MDMA-treated animals
pretreated with THC was similar to the striatum of vehicle-
treated animals. Moreover, TH levels of MDMA-treated animals
housed at 2661uC were significantly reduced when compared to
vehicle treated animals. In contrast, MDMA-treated mice
receiving THC showed similar levels of TH than control
animals (Fig. 7b). These results indicate that the administration
of MDMA at warm ambient temperature strongly exacerbates
DA terminals loss, and that THC attenuates DA terminals
damage and loss induced by MDMA in the striatum of animals
housed at warm temperature. No differences in TrH or SERT
levels were observed in the striatum, prefrontal cortex or
hippocampus of animals treated with MDMA (data not shown).
This result indicates that MDMA specifically damage DA but not
5-HT terminals in mice.
TH levels were also measured in animals pretreated with the
CB1 receptor antagonist AM251 and the CB2 receptor antagonist
AM630 receiving THC and MDMA and housed at 2661uC
(Fig. 7c). THC did not prevent MDMA-induced hyperthermia in
mice treated with AM251. Conversely, AM630 did not modify
the ability of THC to prevent MDMA-induced hyperthermia
(Table 2).
Finally, TH levels were evaluated in CB1,C B 2 and double CB1/
CB2 knockout mice administered with THC and MDMA (Fig. 7b).
Vehicle-treated CB1,C B 2 and double CB1–CB2 knockout mice
showed similar TH levels than wild-type mice. In contrast, THC
prevented MDMA-induced hyperthermia in wild-type and CB2
knockout mice, but it was unable to prevent MDMA-induced DA
terminal loss in mice deficient in the CB1 and CB1–CB2 receptor.
In conclusion, THC protects against MDMA-induced DA axonal
degeneration through the activation of CB1 receptor.
Discussion
In this study, we show that THC prevents MDMA neurotox-
icity not only at room temperature, in which brain damage is mild,
but also at warm temperature, where the neurotoxic effects of
MDMA are strongly enhanced [7,8]. Many reports describe that
MDMA-induced neurotoxicity is directly related to its hyperther-
mic effect, and that MDMA-induced hyperthermia is proportional
to the environmental temperature [8]. For that reason, we tested
the hypothermic and neuroprotective effects of THC on MDMA
neurotoxicity at both 21uC (room temperature) and 26uC (warm
temperature). The hypothermic effects of THC are well known
[15], suggesting that THC might be a good candidate to prevent
MDMA-induced hyperthermia and neurotoxicity. Furthermore,
the anti-inflammatory properties of THC have been widely
reported, and cannabinoid drugs have been shown to exhibit
strong neuroprotective effects on a wide variety of central nervous
system (CNS) disorders [25]. Thus they might contribute to
attenuate MDMA neurotoxicity. Additionally, THC seems to have
neuroprotective effects mediated by receptor independent mech-
anisms due to its antioxidant properties [17,26]. Cannabis, whose
main psychoactive compound is THC, is a drug consumed by
95% of MDMA users. The frequent co-use of both drugs makes it
particularly interesting to study the effects of their combination.
Indeed, previous studies describe the effects of THC and MDMA
together in animal models of locomotor activity, temperature,
anxiety [18], reward [27] and THC-dependence [19]. However,
the neuroprotective effects of THC on MDMA neurotoxicity have
never been reported. In addition, the dose of THC used in this
study (3 mg/kg, i.p.) could be considered a dose consumed by
regular moderate cannabis users, and for that reason similar doses
are used in the previously reported animal studies [18,27].
First, we studied the effects of THC on MDMA-induced
hyperthermia. Mice housed at room temperature (21uC) showed a
moderated hyperthermia when exposed to MDMA, but severe
hyperthermia when room temperature was raised to 26uC. When
THC was administered to MDMA-treated animals, hyperthermia
Table 2. Two-way ANOVA calculated for body temperature and astrocytes and microglia activation in mice treated with THC and
MDMA.
21uC Genotype p-value Treatment p-value Interaction p-value
Body temperature Genotype x treatment F(3, 120)=10.007 P,0.001 F(3, 120)=44.483 p,0.001 F(9, 120)=4.540 p,0.001
CD11b Genotype x treatment F(3, 63)=6.673 p,0.001 F(2, 63)=87.306 p,0.001 F(6, 63)=6.921 p,0.001
GFAP Genotype x treatment F(3, 59)=6.491 p,0.001 F(2, 59)=85.306 p,0.001 F(6, 59)=4.120 p,0.01
26uC Ambient temperature Treatment Interaction
Body temperature Ambient temperature x treatment F(1, 88)=18.498 p,0.001 F(3, 88)=35.861 p,0.001 F(3, 88)=5.270 p,0.001
CD11b Ambient temperature x treatment F(1, 29)=6.417, p,0.05 F(2, 29)=47.921 p,0.001 F(2, 29)=6.725 p,0.01
GFAP Ambient temperature x treatment F(1, 26)=16.683 p,0.001 F(2, 26)=107.930 p,0.01 F(2, 26)=16.744 p,0.001
Two-way ANOVA with genotype, ambient temperature or treatment as between-subject factors. See Materials and methods for details.
doi:10.1371/journal.pone.0009143.t002
Figure 1. THC prevents MDMA-induced hyperthermia at room
temperature. Effects of THC (3 mg/kg, i.p.) on MDMA (20 mg/kg, i.p.)-
induced hyperthermia in animals housed at 2161uC. Body temperature
was measured 30 min after each the first MDMA injection. Data are
expressed as mean 6 SEM of the body temperature increase (n=10).
w p,0.05, www p,0.001 when compared with vehicle-treated group.
qqq p,0.001, when compared with MDMA-treated group (Tukey’s test).
doi:10.1371/journal.pone.0009143.g001
THC Prevents MDMA Toxicity
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9143was prevented in both, mice housed at 21uCa n da t2 6 uC.
Consistent with our results, previous studies described that THC
attenuated MDMA-mediated hyperthermia in rats [18]. More-
over, unlike MDMA, the effects of THC on body temperature
were not affected by ambient temperature. These data indicate
that the mechanisms by which THC reduces body temperature
are different from those mediating MDMA-induced hyperther-
mia. While THC specifically activates CB1 receptors in the
preoptic anterior hypothalamus causing hypothermia [28],
MDMA impairs thermoregulation by altering DA and 5-TH
systems [29]. To find out the mechanism by which THC prevents
MDMA-induced hyperthermia, both THC and MDMA were
administered to animals pretreated with the CB1 receptor
antagonist AM251 or the CB2 receptor antagonist AM630, as
well as in mice lacking the CB1,C B 2 or both cannabinoid
receptors. THC was unable to prevent MDMA-induced hyper-
thermia in mice treated with AM251 or in mice deficient in the
CB1 receptor. These data are consistent with other studies that
described the unability of THC to avoid MDMA-induced
hyperthermia in animals pretreated with the CB1 antagonist
rimonabant. On the contrary, neither the administration of
AM630 nor the deletion of CB2 receptor gene modified the ability
of THC to prevent MDMA-induced hyperthermia. These results
suggest that the hypothermic effects of THC, which are mediated
by the activation of CB1 receptor [30], are responsible for
preventing MDMA-induced hyperthermia, and that CB2 recep-
tor has not a predominant role on this effect. Furthermore, there
is evidence that the absence of CB1 receptor also participates in
the expression of MDMA induced hyperthermia [31], indicating
that not only the pharmacological activation of this receptor,
but its physiological function plays an important role in the
hyperthermic effects of MDMA.
Figure 2. THC prevents MDMA-induced microglial activation through CB1 and CB2 receptor activation. Upper panel: CD11b staining in
the striatum of wild-type (a–c), CB1 (d–f) CB2 (g–i), and double CB1/CB2 (j–l) knockout mice treated with MDMA (20 mg/kg, i.p.) and THC (3 mg/kg,
i.p.), and housed at 2161uC Animals were sacrificed and brains removed 48 h after the last injection. Scale bar, 100 mm. Lower panel: Data on
microglial staining quantification (lower panel) are expressed as mean 6 SEM of percentage of stained area (n=3–6). w p,0.05, ww p,0.01,
www p,0.001 when compared with vehicle-treated group. q p,0.05, qqq p,0.001, when compared with MDMA-treated group. 111 p,0.001,
when compared with wild-type group (Tukey’s test).
doi:10.1371/journal.pone.0009143.g002
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damage. Astrocytes and microglia are activated with minimal
alterations in the CNS, and are considered sensitive markers of
brain damage. For that reason, we evaluated the effects of THC
on MDMA-induced glial activation. MDMA induced a strong
activation of microglia and astrocytes in animal housed at both 21
and 26uC, as previously reported [9,10]. Nevertheless, the
administration of THC significantly reduced glial activation in
animals housed at both 21 and 26uC. These results agree with
previous studies describing that the decrease of MDMA-induced
hyperthermia also attenuates glial activation [9,32]. However, the
well known anti-inflammatory properties of THC may also
contribute to the reduction of MDMA-induced glial activation.
To find out if THC inhibited MDMA-induced microglial and
astrocytes activation by preventing hyperthermia or by reducing
inflammation, glial activation was evaluated in CB1,C B 2 and
double CB1/CB2. THC was unable to prevent glial activation in
CB1 and double CB1/CB2 receptor deficient mice. CB1 receptor is
necessary to induce the hypothermic properties of THC, which
would prevent MDMA hyperthermia and, consequently, cell
damage. Furthermore, THC only partially suppressed MDMA-
induced astrocytes and microglia activation in CB2 knockout mice.
Microglia cells express CB2 cannabinoid receptor [33], which
mediated the anti-inflammatory properties of THC [34]. In many
cases, severe microglia activation exacerbates inflammation and
brain damage instead of reducing it due to the high amount of
inflammatory mediators, such as cytokines and nitric oxide,
released by these cells [35]. Thus, the activation of CB2 receptor
by THC contributes to attenuate microglial activation and, as a
result, to reduce cell damage. Thus, both CB1 and CB2 receptors
mediate the THC-induced prevention of MDMA-induced glial
activation and cell damage. Furthermore, the receptor-indepen-
dent antioxidant properties of THC may also contribute to
prevent brain damage [17,26]. However, mice deficient in both
CB1 and CB2 receptors treated with THC and MDMA show the
same glial activation than animals treated with MDMA alone.
This result indicates that antioxidant properties of THC do not
contribute to reduce MDMA neurotoxic effects.
Figure 3. THC prevents MDMA-induced astrocytes activation through CB1 and CB2 receptor activation. Upper panel: GFAP staining in
the striatum of wild-type (a–c), CB1 (d–f) CB2 (g–i), and double CB1/CB2 (j–l) knockout mice treated with MDMA (20 mg/kg, i.p.) and THC (3 mg/kg,
i.p.), housed at 2161uC. Animals were sacrificed and brains removed 48 h after the last injection. Scale bar, 100 mm. Lower panel: Data on astrocytes
staining are expressed as mean 6 SEM of percentage of stained area (n=3–6). w p,0.05, ww p,0.01, www p,0.001 when compared with vehicle-
treated group. qqq p,0.001, when compared with MDMA-treated group. 111 p,0.001, when compared with wild-type group (Tukey’s test).
doi:10.1371/journal.pone.0009143.g003
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glial activation resulted in DA axonal loss, we assessed the integrity
of DA striatum terminals. DA axons were stained and TH levels
were measured in the striatum of mice treated with THC and
MDMA and housed at 21 or 26uC. Surprisingly, mice treated with
MDMA at 21uC did not show a significant alteration of striatum
structure or decrease in TH levels. This result indicates that the
cell damage and the consequent inflammation induced by MDMA
in animals housed at 21uC were not strong enough to destroy DA
nerve terminals. In contrast, MDMA-treated animals housed at
26uC showed an important alteration of striatum structure and a
significant decrease of TH levels. These results agree with previous
reports describing that the enhancement in MDMA-induced
hyperthermia caused by warm ambient temperature also enhances
MDMA neurotoxicity [8]. Strikingly, MDMA induced a strong
microglia and astrocytes activation at both 21 and 26uC ambient
temperatures. Microglia and astrocytes are extremely sensitive to
even small pathological changes in the CNS [36], whereas a strong
change is required to observe significant changes in striatum
structure and TH levels. Thus, the moderated hyperthermia
induced by MDMA to animals housed at 21uC caused mild
neuronal damage, which elicited an inflammatory reaction, but
did not destroy DA axons or reduce TH levels. On the contrary,
the strong hyperthermia induced by MDMA at 26uC caused
severe neuronal damage that triggered a marked glial activation,
an important alteration of the striatum structure, and a significant
reduction of TH levels. Our results are supported by other studies
showing that warm ambient temperature enhances MDMA
neurotoxicity by promoting the formation of neurotoxic deriva-
tives [7], and by enhancing the uptake of these metabolites inside
Figure 4. MDMA does not decrease TH levels in the striatum at room temperature. TH immunostaining (a) and protein levels (b) in the
striatum of animals treated with THC (3 mg/kg, i.p.) and MDMA (20 mg/kg, i.p.) housed at 2161uC. Animals were sacrificed and tissue was removed
48 h after the last injection. A representative TH immunostaining (a) is shown. TH band densities (b) were quantified. Data are expressed as mean 6
SEM of percentage of density compared to controls (n=3).
doi:10.1371/journal.pone.0009143.g004
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9143Figure 5. THC prevents MDMA-induced hyperthermia at warm temperature by activating CB1 receptor. Effects of pretreatment with
THC (3 mg/kg, i.p.) on MDMA (20 mg/kg, i.p.)-induced hyperthermia in (a) wild-type, CB1,C B 2 and double CB1/CB2 knockout animals housed at
26u61uC, (b) wild-type animals treated with THC and MDMA at 21 and 26u61uC, and wild-type animals treated with (c) AM251 or (d) AM630, THC and
MDMA at 26uC. Body temperature was measured 30 min after MDMA injection (90 min after THC injection). Data are expressed as mean 6 SEM of the
body temperature increase (n=6–7). All values are expressed as mean 6 SEM. ww p,0.01, www p,0.001 when compared with vehicle-treated
group. qq p,0.01, qqq p,0.001 when compared with wild-type group. 1 p,0.05, 11 p,0.01, 111 p,0.001 when compared with wild-type
animals or animals housed at 2161uC (Tukey’s test or one-way ANOVA).
doi:10.1371/journal.pone.0009143.g005
Figure 6. THC prevents MDMA-induced glial activation at both room and warm temperature. CD11b (a) and GFAP (b) staining
quantification in mice housed at 21 and 2661uC. Data are expressed as mean 6 SEM of percentage of stained area (n=3–7). www p,0.001 when
compared with vehicle-treated group. qqq p,0.001 when compared with MDMA-treated group. 1 p,0.05, 11 p,0.01, when compared with
animals housed at 2161uC (Tukey’s test or one-way ANOVA).
doi:10.1371/journal.pone.0009143.g006
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may attenuate the formation and uptake of toxic metabolites and
prevent MDMA neurotoxicity. Therefore, we evaluated the effect
of THC on MDMA-induced DA axonal loss in the striatum of
animals housed at 26uC. The striatum of animals treated with
THC and MDMA showed similar structure and staining intensity
compared with the striatum of saline-treated animals, whereas the
striatum of MDMA-treated mice showed a decreased staining and
an altered structure. In addition, TH levels in the striatum were
similar between saline-treated animals and animals treated with
both THC and MDMA, whereas they were strongly reduced in
animals treated with MDMA. Thus, THC prevents the destruc-
tion of DA axons induced by MDMA at high ambient
temperature. To find out the mechanism by which THC prevents
DA axonal loss, animals treated with THC and MDMA were
pretreated with the CB1 antagonist AM251 and the CB2
Figure 7. THC prevents MDMA-induced reduction ofTH levels in the striatum through CB1 activation. Striatum TH immunostaining of wild-
type animals treated withTHC (3 mg/kg, i.p.) and MDMA(20 mg/kg,i.p.) housed at 2661uC.A representativeTH immunostaining of the whole brain, and
10x images are shown (a). TH protein levels of wild-type, CB1, CB2, and double CB1/CB2 knockout mice (b) and AM251 and AM630-treated mice (c),
receiving THC (3 mg/kg, i.p.) and MDMA (20 mg/kg, i.p.) and housed at 2661uC. A representative TH immunoblot from striatum homogenates is shown.
Animals were sacrificed and tissue was removed 48 h after the last injection. TH band densities were quantified. Data are expressed as mean 6 SEM of
percentage of density compared to controls (n=3).ww p,0.01, www p,0.001 when compared with vehicle-treated group. q p,0.05, qqq p,0.001
when compared with MDMA-treated group. 1 p,0.05, 11 p,0.01, when compared with wild-type group (Tukey’s test).
doi:10.1371/journal.pone.0009143.g007
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nal loss in mice pretreated with AM630 but not with AM251.
These results indicate that the activation of CB1 but not CB2
receptor is necessary for THC to prevent MDMA-induced DA
axons destruction. Nevertheless, acute pharmacological blockade
of cannabinoid receptors does not inhibit cannabinoid receptor
permanently during all the process and axonal degeneration. For
that reason, the mechanism by which THC prevents MDMA-
induced axonal damage was also evaluated in CB1, CB2 and
double CB1/CB2 knockout mice. CB1 and double CB1/CB2
knockout mice treated with THC and MDMA showed similar TH
levels than mice treated with MDMA alone, suggesting that the
hypothermic effects of THC mediated by CB1 receptor are
responsible for preventing DA terminals destruction. However, no
difference between CB1 knockout mice and double CB1-CB2
knockout treated with both THC and MDMA was observed.
Furthermore, no difference between CB2 knockout mice and wild-
type mice receiving THC and MDMA was observed. Additionally,
we observed difference between CB1 knockout mice treated with
THC and MDMA together and MDMA alone. Altogether, these
results indicate that the anti-inflammatory properties of THC
mediated by CB2 receptor do not significantly contribute to
prevent DA terminal loss.
In summary, THC completely prevents MDMA-induced
hyperthermia, glial activation and DA axonal loss by inducing
CB1 receptor-mediated hypothermia. THC anti-inflammatory
properties mediated by CB2 receptors also reduced microglia
and astrocytes activation induced by MDMA. However, THC
receptor-independent antioxidant properties do not seem to
contribute to reduce MDMA neurotoxicity. Although it has been
previously reported that other drugs reducing MDMA-induced
hyperthermia also reduced MDMA neurotoxicity [9], these drugs
are not used by potential MDMA users. On the contrary, 95% of
MDMA users also consume cannabis [14,21] and, consequently,
THC. Some clinical studies have shown that the use of cannabis
and MDMA usually results in neurocognitive deficits and
neuropsychiatric symptoms, especially in long-lasting heavy users
[38–40]. However, clinical data suggest the possibility that THC
may protect against the neurotoxic effects of MDMA, since several
neurological symptoms were attenuated in THC and MDMA
consumers when compared to pure MDMA users [21,41,42].
Indeed, the use of THC to prevent MDMA-induced hyperthermia
and neurotoxicity does not seem to be an adequate measure.
However, this study elucidates the consequences of drug polyuse
which is one of the main concerns in the study of drugs of abuse,
especially MDMA.
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